| Name | Title | Contact Details |
|---|
Second Genome is a clinical stage company with a mission to improve human health by unlocking the full potential of the microbiome. We offer the most robust approach to microbiome drug discovery and development through the deepest understanding of how the microbiome works in human health.
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
Walter Payton Cancer Fund is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PNP Therapeutics is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Labs-Now is a Garrett Park, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.